TTI-0102
Asset
Sustained-release cysteamine prodrug that depletes cystine and supports intracellular cysteine and glutathione production.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- ACE2
- 6
- Indications
- 0
- Trials
- 1
- Developer
Indications
6Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes
Phase 2, thiogenesis.com, 10 Oct 2026
Nephropathic cystinosis
Phase 2, thiogenesis.com, 10 Oct 2026
SARS
Phase 2, thiogenesis.com, 10 Oct 2026
3 more
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors2
Every asset’s record: target, stage, trials and the evidence behind it.